Teva Pharmaceuticals this week launched Lenalidomide, a generic alternative to Bristol Myers Squibb’s Revlimid, for the treatment of multiple myeloma. It is the first of several generic challengers to launch. For the treatment of multiple myeloma, Revlimid currently holds covered or better status for 99% of all insured lives. 17.6% of all covered lives have preferred access to Revlimid without utilization management restrictions.
SOURCE: MMIT Analytics, as of 3/8/22